Line 64: |
Line 64: |
| Preventative strategies should also be implemented in the FIV-infected animal in order to protect the cat from acquiring potentially life-threatening infections. This is particularly important as FIV positive animals are often refractory to treatment when secondary infections arise. Ideally, affected cats should be kept indoors to minimise exposure to potential pathogens<sup>4</sup>. Routine vaccination against herpesvirus, calicivirus and panleukopenia and possibly feline leukaemia virus is recommended<sup>2</sup>, and killed vaccines should be favoured as there is a small risk of the attenuated strains in modified live vaccines causing disease in the immunosuppressed patient<sup>2, 5</sup>. It may also be advisable to administer an extra booster before introducing the cat to a high risk environment, such as a cattery or in hospitalisation if the cat has not received one in the last six months<sup>2</sup>. Treatment against worms and fleas should be kept up to daye, particularly to minimise the risk of transmission of ''Haemobartonella felis''. | | Preventative strategies should also be implemented in the FIV-infected animal in order to protect the cat from acquiring potentially life-threatening infections. This is particularly important as FIV positive animals are often refractory to treatment when secondary infections arise. Ideally, affected cats should be kept indoors to minimise exposure to potential pathogens<sup>4</sup>. Routine vaccination against herpesvirus, calicivirus and panleukopenia and possibly feline leukaemia virus is recommended<sup>2</sup>, and killed vaccines should be favoured as there is a small risk of the attenuated strains in modified live vaccines causing disease in the immunosuppressed patient<sup>2, 5</sup>. It may also be advisable to administer an extra booster before introducing the cat to a high risk environment, such as a cattery or in hospitalisation if the cat has not received one in the last six months<sup>2</sup>. Treatment against worms and fleas should be kept up to daye, particularly to minimise the risk of transmission of ''Haemobartonella felis''. |
| | | |
− | Agents such as the reverse transcriptase inhibitor AZT
| + | Some antiviral agents have been shown to give improvement in FIV-infected cats<sup>2</sup>. Zidovudine is the mot effective of these<sup>5</sup> but can induce bone marrow toxicity and so patients' haematological profile should be closely monitored<sup>2, 4, 5<sup>. |
− | (3'-azido-3'-deoxythymidine) and the immunostimulator
| + | |
− | interleukin-2 have been used in a small number of
| |
− | clinical trials involving FIV-infected cats with chronic
| |
− | gingivitis/stomatitis. Improvements in clinical and laboratory
| |
− | findings were reported in a proportion of these cats
| |
− | treated orally or subcutaneously with AZT at a dose of 5
| |
− | mg/kg three times daily (Hartmann and others 1992, Hart
| |
− | and Nolte 1995, Hartmann and others 1995). Since
| |
− | anaemia is a potential adverse effect of this agent, haematology
| |
− | should be assessed regularly in cats receiving this
| |
− | treatment. It should be noted that neither AZT nor interleukin-
| |
− | 2 are licensed for veterinary use.
| |
| Evening primrose oil, at a suggested dose rate of | | Evening primrose oil, at a suggested dose rate of |
| one 550 mg capsule daily, has also been used with | | one 550 mg capsule daily, has also been used with |